#WhatsYourPlan campaign results in 20 commitments to implement National Dementia Plans
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
ADI members in the Caribbean call for urgent action on dementia
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
145 Indigenous languages and no word for dementia: use of innovation and technology to help overcome stigma
In this case study excerpt for the World Alzheimer Report 2019, Maree McCabe, CEO of Dementia Australia, writes about the importance of culturally sensitive diagnostic methods when addressing dementia within Indigenous Australian communities.
Stigma and response to dementia in Guatemala’s Indigenous population
In this case study excerpt for the World Alzheimer Report 2019, María Cecilia López Murga, Executive of Asociación Group Ermita Alzheimer de Guatemala, writes about how the association's mission to address the challenges around dementia within Guatemala’s Indigenous communities.
The circle of life: Indigenous knowledge about dementia in Canada
In this case study excerpt for the World Alzheimer Report 2019, Kristen Jacklin and Karen Pitawanakwat write about understanding the experiences of dementia within Indigenous communities in order to meet dementia care needs in a culturally sensitive way.
Spominčica – Alzheimer Slovenija – Dementia Friendly Spots
In 2016 Spominčica – Alzheimer Slovenija started developing the Dementia Friendly Spots (DFS) programme. It is a national education and awareness-raising programme connecting a wide spectrum of organisations in a network of sites providing information about dementia locally. The network of DFS include: police and fire stations, shops, libraries,…
China approves first drug for mild to moderate Alzheimer’s in 17 years
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Thinking more deeply about dementia friendly initiatives
This piece questioning how we see and understand dementia friendly communities, their role and how they may evolve was contributed to the World Alzheimer Report 2019 by Glenn Rees, Chair of ADI, and Dr Linda Barclay, a Senior Lecturer in Philosophy at Monash University who specialises in disability and justice.
Biogen and Eisai announce plans to file for market approval of Alzheimer’s drug
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Dementia given high priority at G20 Health Ministers Meeting
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.